19:08 , Apr 20, 2018 |  BC Week In Review  |  Company News

Basilea gains rights to ArQule's derazantinib

ArQule Inc. (NASDAQ:ARQL) granted Basilea Pharmaceutica Ltd. (SIX:BSLN) exclusive rights to develop and commercialize derazantinib (ARQ 087) outside of Taiwan and China, including Hong Kong and Macau. Derazantinib is a pan-fibroblast growth factor (FGF) receptor...
19:09 , Apr 17, 2018 |  BC Extra  |  Company News

Basilea gains rights to ArQule's derazantinib

ArQule Inc. (NASDAQ:ARQL) shares rose $0.46 (17%) to $3.16 on Tuesday after it granted Basilea Pharmaceutica Ltd. (SIX:BSLN) exclusive rights to develop and commercialize derazantinib (ARQ 087) outside of Taiwan and China, including Hong Kong...
07:00 , May 11, 2015 |  BC Week In Review  |  Clinical News

BAL3833: Phase I started

Basilea announced the start of an open-label, dose-escalation, U.K. Phase I trial to evaluate once-daily oral BAL3833 in adult patients. Basilea has exclusive, worldwide rights to develop and commercialize BAL3833 under an April deal with...